Stockhub

Frequency Therapeutics, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

20 August 2022

12 August 2022

28 July 2022

  • curprev 21:5621:56, 28 July 2022‎ Chris talk contribs‎ 1,075 bytes +1,075‎ Created page with "Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also dev..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Frequency_Therapeutics,_Inc.’